JAK/TYK2

      More on TLL-018

      How?
      A: Everyone surprised. But maybe dual mech benefits re: pain via IFN

      Where’s the multinational

      David Liew drdavidliew

      2 years ago
      More on TLL-018 How? A: Everyone surprised. But maybe dual mech benefits re: pain via IFN Where’s the multinational RCT in RA? A: Priority on rapid registration in China, quickly. But ph2 trials for psoriasis happening in US, results so far look consistent. #ACR23 @RheumNow
      older woman with clasped hands
      Who gives a ‘JAK’ why and how they work, as long as they do!
      2 years ago
      Several abstracts have studied the mechanism of action of JAK inhibitors (JAKi) in various diseases. JAKi alter many other mediators affected by the JAK STAT pathway. For instance, T cell signature in blood that is proliferative was associated with a response in RA.
      Fascinating how upadacitinib may well have an effect on pain in RA, beyond inflammation.

      Now seen similar for bari in R

      David Liew drdavidliew

      2 years ago
      Fascinating how upadacitinib may well have an effect on pain in RA, beyond inflammation. Now seen similar for bari in RA & guselkumab in PsA. And, if real, for some people could be a massive get. Love to see dedicated studies SELECT-COMPARE post-hoc #ACR23 ABST0429 @RheumNow https://t.co/Tk278mGJYY
      Ab#0596 #ACR23 @RheumNow
      R Furie on Decravacitinib in SLE
      48wk double-blind trial. PBO v DEU 3mgBID, 6 mgBID,12 mg qd
      H

      Eric Dein

      2 years ago
      Ab#0596 #ACR23 @RheumNow R Furie on Decravacitinib in SLE 48wk double-blind trial. PBO v DEU 3mgBID, 6 mgBID,12 mg qd Higher response, faster time to SRI(4), BICLA and dual response v PBO. More likely to sustain response from w32-48. https://t.co/M34d3nQmwv
      Abs#518 @RheumNow #ACR23
      Deodhar: TOFA in AS, by b/l CRP levels
      30% nml CRP (<5 mg/L) v 70% Elevated
      At wk 12, TOFA &

      Eric Dein

      2 years ago
      Abs#518 @RheumNow #ACR23 Deodhar: TOFA in AS, by b/l CRP levels 30% nml CRP (<5 mg/L) v 70% Elevated At wk 12, TOFA >> PBO regardless of b/l CRP Difference in response: greater in pts w elevated CRP Safety rates: elev. CRP c/w PBO, but nml CRP had trend of high AEs for tofa v PBO https://t.co/b9NRNkU8ub
      Upadacitinib on wearable device-measure activity
      SELECT-AXIS 2
      Abs#0530 #ACR23 @RheumNow
      UPA had numerically higher mea

      Eric Dein

      2 years ago
      Upadacitinib on wearable device-measure activity SELECT-AXIS 2 Abs#0530 #ACR23 @RheumNow UPA had numerically higher mean daily step counts than PBO 11% improvement v PBO at wk 14 (diff of 345 steps/day) Sedentary pts: 22% improvement in daily step count from b/l on UPA (4% PBO) https://t.co/Gq91TmvfZC
      Good Treatment review of biologics (IL-1, IL-6) in systemic JIA (Stills) including complications of #MAS and lung diseas

      Dr. John Cush RheumNow

      2 years ago
      Good Treatment review of biologics (IL-1, IL-6) in systemic JIA (Stills) including complications of #MAS and lung disease; also info on horizon therapies like JAK inhibitors and IL-18 targeting and novel biomarkers (calgranulins, IL-18 and CXCL9) https://t.co/Cbd7bKdIbb https://t.co/d9tn9fmSAy
      Tofacitinib efficacy and safety in axSpA pts by baseline CRP levels
      Elevated CRP pts with higher response in ASAS20, ASA

      Robert B Chao, MD

      2 years ago
      Tofacitinib efficacy and safety in axSpA pts by baseline CRP levels Elevated CRP pts with higher response in ASAS20, ASAS40, BASDAI50, etc. AE trended higher in normal CRP pts taking Tofa compared to placebo @RheumNow #ACR23 Abs#0518 https://t.co/nbiD36x1Pa
      Deucravacitinib (TYK2) data has been surprisngly good in SLE

      Strong rationale in PsA as well; I liked this poster &

      Mike Putman EBRheum

      2 years ago
      Deucravacitinib (TYK2) data has been surprisngly good in SLE Strong rationale in PsA as well; I liked this poster & the focus on pain scores / patient QOL Probably my #1 draft pick for "drugs I'm buying right now" @RheumNow #ACR23 Abstr0508 https://t.co/FHNvgUrYxp
      Year in Review: Dr. P Seo

      Novel PsA therapy on the horizon:

      ⭐️Brepocitinib
      ➡️ Tyk-2 inhibitor: IL12/23 & t

      Meral K. El Ramahi, MD MeralElRamahiMD

      2 years ago
      Year in Review: Dr. P Seo Novel PsA therapy on the horizon: ⭐️Brepocitinib ➡️ Tyk-2 inhibitor: IL12/23 & type I IFN ➡️ Phase Ib, 218 pts, 8% TNFi failure ➡️ 71% on concurrent MTX ➡️ Wk 16: ACR 50/70 & PASI75/90 improved, maintained through week 52 #ACR23 @RheumNow
      I’m not TYK’ed! Another TYK2 #TAK-279 in #PsA RCT. Yup it works in ballpark of other PsA #Rx. #PASI75 45.7%. No obvi

      Janet Pope

      2 years ago
      I’m not TYK’ed! Another TYK2 #TAK-279 in #PsA RCT. Yup it works in ballpark of other PsA #Rx. #PASI75 45.7%. No obvious dose response w 15 and 30 mg daily but more #acne at higher dose. #ACR23 @ACRheum @RheumNow poster L12 Where to use vs #Deucravitinib? Too early to say as Ph2 https://t.co/nMkgOlUf6s
      Nice VA study evaluating risk of lung cancer w/respect to RA treatment strategies

      Take home? No association. Aside from

      Mike Putman EBRheum

      2 years ago
      Nice VA study evaluating risk of lung cancer w/respect to RA treatment strategies Take home? No association. Aside from the (small risk) w/JAKi's, I think malignancy risks have been mostly overblown @NamrataRheum @RheumNow ABST0453 #ACR23 https://t.co/lDz0nV1KHt
      Patient reported outcomes between clinic visits: worth doing?

      RA pts starting ADA/UPA, n=150
      ArthritisPower/PatientSpot

      David Liew drdavidliew

      2 years ago
      Patient reported outcomes between clinic visits: worth doing? RA pts starting ADA/UPA, n=150 ArthritisPower/PatientSpot app for PROs between visits 52% of CDAI change explained by PROs Maybe a helpful tool in prioritising RA clinic reviews? @RADoctor #ACR23 ABST0380 @RheumNow https://t.co/oTttAlIxQR
      Who knew? VEXAS =cluster of findings from a somatic mutation N=110 studying retention of advanced Rx. #JAKi had far bett

      Janet Pope

      2 years ago
      Who knew? VEXAS =cluster of findings from a somatic mutation N=110 studying retention of advanced Rx. #JAKi had far better retention than other #Rx. Although there could be channeling bias, I am impressed! Access for off label is a different issue #L03 #ACR23 @RheumNow @ACRheum https://t.co/RE4BVdZeWt
      steroids.prednisone.pills_.jpg
      Glucocorticoids-free zone in SLE?
      2 years ago
      For over 70 years, glucocorticoids, (GC) have been a part of standard therapy in SLE. They are classically used to not only induce remission or treat an acute flare, but also as maintenance therapy. They are a valuable 'friend' if used wisely, and can become a 'foe' if used excessively.

      Catch up on Conference Podcasts

      ×